Trial Rethink: New Medical Journal Paradigm Should Factor Into Study Plans

Firms may need to become more selective in deciding which trials to conduct if a barrage of negative results are to be avoided, Robert Klepinski, president of Klepinski and DuVal, advised during a recent Regulatory Affairs Professionals Society meeting in Washington, D.